Correlation of NRAS Mutations with Clinical Response to High Dose IL-2 in Patients with Advanced Melanoma

Por Joseph, R. W., Sullivan, R. J., Harrell, R., Stemke-Hale, K., Panka, D., Manoukian, G., Percy, A., Bassett, R. L., Ng, Chaan S., Radvanyi, Laszlo, Hwu, P., Atkins, M. B., Davies, M. A.
Publicado em 2012

RALB provides critical survival signals downstream of Ras in acute myeloid leukemia

Por Eckfeldt, Craig E., Pomeroy, Emily J., Lee, Robin D.W., Hazen, Katherine S., Lee, Lindsey A., Moriarity, Branden S., Largaespada, David A.
Publicado no Oncotarget (2016)

Early Transcriptional Response of Soybean Contrasting Accessions to Root Dehydration

Por Ferreira Neto, José Ribamar Costa, Pandolfi, Valesca, Guimaraes, Francismar Corrêa Marcelino, Benko-Iseppon, Ana Maria, Romero, Cynara, Silva, Roberta Lane de Oliveira, Rodrigues, Fabiana Aparecida, Abdelnoor, Ricardo Vilela, Nepomuceno, Alexandre Lima, Kido, Ederson Akio
Publicado em 2013

Sensitivity of plasma BRAF(mutant) and NRAS(mutant) cell‐free DNA assays to detect metastatic...

Por Chang, Gregory A., Tadepalli, Jyothirmayee S., Shao, Yongzhao, Zhang, Yilong, Weiss, Sarah, Robinson, Eric, Spittle, Cindy, Furtado, Manohar, Shelton, Dawne N., Karlin-Neumann, George, Pavlick, Anna, Osman, Iman, Polsky, David
Publicado no Mol Oncol (2015)

Naturally Occurring Canine Melanoma as a Predictive Comparative Oncology Model for Human Mucosal and Other Triple Wild-Type Melanomas

Por Hernandez, Belen, Adissu, Hibret A., Wei, Bih-Rong, Michael, Helen T., Merlino, Glenn, Simpson, R. Mark
Publicado no Int J Mol Sci (2018)

MiR-26a Enhances the Sensitivity of Gastric Cancer Cells to Cisplatin by Targeting NRAS and E2F2

Por Wen, Lan, Cheng, Fangzhi, Zhou, Yanyan, Yin, Chunhua
Publicado no Saudi J Gastroenterol (2015)

Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer

Por Kleist, Britta, Kempa, Marcel, Novy, Michael, Oberkanins, Christian, Xu, Li, Li, Guojun, Loland, Christiane, Poetsch, Micaela
Publicado em 2014

Heterogeneity of expression of epithelial–mesenchymal transition markers in melanocytes and melanoma cell lines

Por Kim, Ji Eun, Leung, Euphemia, Baguley, Bruce C., Finlay, Graeme J.
Publicado em 2013

The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions

Por Bolouri, Hamid, Farrar, Jason E, Triche, Timothy, Ries, Rhonda E, Lim, Emilia L, Alonzo, Todd A, Ma, Yussanne, Moore, Richard, Mungall, Andrew J, Marra, Marco A, Zhang, Jinghui, Ma, Xiaotu, Liu, Yu, Liu, Yanling, Auvil, Jaime M Guidry, Davidsen, Tanja M, Gesuwan, Patee, Hermida, Leandro C, Salhia, Bodour, Capone, Stephen, Ramsingh, Giridharan, Zwaan, Christian Michel, Noort, Sanne, Piccolo, Stephen R, Kolb, E Anders, Gamis, Alan S, Smith, Malcolm A, Gerhard, Daniela S, Meshinchi, Soheil
Publicado no Nat Med (2017)

Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-bas...

Por Domingo, Enric, Camps, Carme, Kaisaki, Pamela J, Parsons, Marie J, Mouradov, Dmitri, Pentony, Melissa M, Makino, Seiko, Palmieri, Michelle, Ward, Robyn L, Hawkins, Nicholas J, Gibbs, Peter, Askautrud, Hanne, Oukrif, Dahmane, Wang, Haitao, Wood, Joe, Tomlinson, Evie, Bark, Yasmine, Kaur, Kulvinder, Johnstone, Elaine C, Palles, Claire, Church, David N, Novelli, Marco, Danielsen, Havard E, Sherlock, Jon, Kerr, David, Kerr, Rachel, Sieber, Oliver, Taylor, Jenny C, Tomlinson, Ian
Publicado no Lancet Gastroenterol Hepatol (2018)

Development and Characterization of Six New Human Papillary Thyroid Carcinoma Cell Lines

Por Henderson, Ying C., Ahn, Soon-Hyun, Ryu, Junsun, Chen, Yunyun, Williams, Michelle D., El-Naggar, Adel K., Gagea, Mihai, Schweppe, Rebecca E., Haugen, Bryan R., Lai, Stephen Y., Clayman, Gary L.
Publicado no J Clin Endocrinol Metab (2015)

Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition

Por Zimmer, Lisa, Hillen, Uwe, Livingstone, Elisabeth, Lacouture, Mario E., Busam, Klaus, Carvajal, Richard D., Egberts, Friederike, Hauschild, Axel, Kashani-Sabet, Mohammed, Goldinger, Simone M., Dummer, Reinhard, Long, Georgina V., McArthur, Grant, Scherag, André, Sucker, Antje, Schadendorf, Dirk
Publicado em 2012

Mutational and Clinical Predictors of Pathologic Complete Response in the Treatment of Locally Advanced Rectal Cancer

Por Russo, Andrea L., Ryan, David P., Borger, Darrell R., Wo, Jennifer Y., Szymonifka, Jackie, Liang, Wen-Yih, Kwak, Eunice L., Blaszkowsky, Lawrence S., Clark, Jeffrey W., Allen, Jill N., Zhu, Andrew X., Berger, David L., Cusack, James C., Mamon, Harvey J., Haigis, Kevin M., Hong, Theodore S.
Publicado no J Gastrointest Cancer (2014)

Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities

Por Jardim, Denis L Fontes, Conley, Anthony, Subbiah, Vivek
Publicado em 2013

Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations

Por Gollins, Simon, West, Nick, Sebag-Montefiore, David, Myint, Arthur Sun, Saunders, Mark, Susnerwala, Shabbir, Quirke, Phil, Essapen, Sharadah, Samuel, Leslie, Sizer, Bruce, Worlding, Jane, Southward, Katie, Hemmings, Gemma, Tinkler-Hundal, Emma, Taylor, Morag, Bottomley, Daniel, Chambers, Philip, Lawrie, Emma, Lopes, Andre, Beare, Sandy
Publicado no Br J Cancer (2017)